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MEN2A PATIENTS 
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Supervisory Professor: Thereasa Rich, MS, CGC 
The American Thyroid Association recently classified all MEN2A-associated codons 
into increasing risk levels A-C and stated that some patients may delay prophylactic 
thyroidectomy if certain criteria are met.  One criterion is a less aggressive family history of 
MTC but whether families with the same mutated codon have variable MTC aggressiveness 
is not well described.  We developed several novel measures of MTC aggressiveness and 
compared families with the same mutated codon to determine if there is significant inter-
familial variability.  Pedigrees of families with MEN2A were reviewed for codon mutated 
and proportion of RET mutation carriers with MTC.  Individuals with MTC were classified 
as having local or distant MTC and whether they had progressive MTC.  MTC status and age 
were assessed at diagnosis and most advanced MTC stage.  For those without MTC, age was 
recorded at prophylactic thyroidectomy or last follow-up if the patient did not have a 
thyroidectomy.  For each pedigree, the mean age of members without MTC, with MTC, and 
the proportion of RET mutation carriers with local or distant and progressive MTC were 
calculated.  We assessed differences in these variables using ANOVA and the Fisher’s exact 
test.  Sufficient data for analysis were available for families with mutated codons 609 (92 
patients from 13 families), 618 (41 patients from 7 families), and 634 (152 patients from 13 
families).  The only significant differences found were the mean age of patients without 
MTC between families with codon 609 and 618 mutations even after accounting for 
prophylactic thyroidectomy (p=0.006 and 0.001, respectively), and in the mean age of MTC 
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diagnosis between families with codon 618 and 634 mutations even after accounting for 
symptomatic presentation (p=0.023 and 0.014, respectively).  However, these differences 
may be explained by generational differences in ascertainment of RET carriers and the 
availability of genetic testing when the proband initially presented.   
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ABBREVIATIONS 
 
ATA: American Thyroid Association 
CCH: C-cell hyperplasia 
MDACC: MD Anderson Cancer Center 
MEN2: Multiple Endocrine Neoplasia Type 2 
MTC: Medullary Thyroid Cancer 
N0MTC: Medullary Thyroid Cancer with No Lymph Node Metastases 
N1MTC: Medullary Thyroid Cancer with Lymph Node Metastses 
M1MTC: Medullary Thyroid Cancer with Distant Metastases 
NED: No Evidence of Disease by Family Report 
NEDP: No Evidence of Disease (MTC) on Prophylactic Thyroidectomy 
NEDTI: No Evidence of Disease (MTC) with Thyroid Intact 
PHEO: Pheochromocytoma 
PHPT: Primary Hyperparathyroidism 
RET: Rearranged During Transfection Proto-oncogene 
TICt: Thyroid Intact with Elevated Calcitonin
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Background 
Multiple Endocrine Neoplasia 2A (MEN2A) is an autosomal dominant cancer 
predisposition syndrome affecting approximately 1/30,000 people worldwide [1].  It is 
characterized by a high risk for medullary thyroid cancer (MTC) as well as risk for 
pheochromocytoma (PHEO) and primary hyperparathyroidism (PHPT).  The first 
presentation and most common cause of morbidity and mortality in MEN2A is MTC, which 
affects approximately 90% of patients [2,3].  MTC is a malignant neuroendocrine tumor 
comprising approximately 5% of all thyroid cancers but accounting for a disproportionate 
number of thyroid cancer-related mortality [4].  It is derived from the parafollicular 
calcitonin-producing C-cells of the thyroid and starts as C-cell hyperplasia (CCH)  and over 
time leads to MTC, which may then metastasize to cervical lymph nodes and distant organs 
such as the liver, lungs, and bone [3,5].  The treatment for MTC typically includes a total 
thyroidectomy with central neck dissection; additional lymph node dissection may be 
performed if metastases are suspected.  When local lymph node metastases are present, 
treatment is less likely to result in cure, and is typically incurable once spread to distant sites 
[2].  Progression of MTC is typically monitored with the aid of serum calcitonin levels, 
which increase with volume of MTC and may also be elevated in patients with CCH. 
MEN2A is associated with a limited number of recurring germline missense 
mutations in the Rearranged During Transfection proto-oncogene (RET).  Strong genotype-
phenotype correlations are well documented, though significant intra- and inter-familial 
variability exists [2,6].  The American Thyroid Association (ATA) has categorized all known 
MEN2A-causing mutations into  three risk levels based on the aggressiveness of MTC 
associated with each mutation [2].  These risk levels are used to guide the timing of 
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thyroidectomy in pre-symptomatic MEN2A patients, which greatly reduces the risk for an 
advanced thyroid cancer [7,8].  Patients in risk levels A and B may delay surgery beyond five 
years of age if the following criteria are met: a normal neck ultrasound, a normal calcitonin 
measurement, a less aggressive family history of MTC, and if the family would prefer to 
wait.  Patients in risk level C are recommended to have a thyroidectomy by age 5 years, with 
the specific timing dependent upon the findings of ultrasound and calcitonin levels [2].      
While the potential benefits of a prophylactic thyroidectomy are clear, delaying 
surgery may be beneficial for children with less-aggressive RET mutations, although this is 
controversial [9].  In these patients, MTC before the second decade of life is rare and children 
with normal annual calcitonin levels and thyroid ultrasounds are not likely to develop 
metastases [2,10].  Children undergoing thyroid surgery have more complications such as 
vocal cord paresis and hypocalcemia than adults, especially when they do not have access to 
a high-volume surgeon at a multidisciplinary center [9,11].  After surgery, the management 
of hormone therapy may be challenging for both the patient and family [9]. These 
considerations suggest that delaying prophylactic thyroidectomy may be a valid option for 
some patients, though the ideal timing of thyroidectomy and safety of delayed thyroidectomy 
is still unclear [3].   
Most of the criteria proposed by the ATA for delaying thyroidectomy have been 
evaluated with regard to effectiveness of predicting the presence of MTC.  Annual serum 
calcitonin screening is a powerful method used to screen for MTC and has been validated in 
many studies [12,13,14,15].  A serum calcitonin level of less than 40 pg/ml strongly indicates 
metastases are not present [8,16].  Limitations of calcitonin screening are also well studied, 
and this method may miss early MTCs [17].  Recently, a study evaluating ultrasound in 
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pediatric patients with MEN2A concluded it is not a useful method to detect microscopic 
MTC and performs with a sensitivity of only 13% [18].    
The criterion of a “less aggressive family history” is not well defined.  To our 
knowledge, no studies have established the relationship between family history of MTC and 
MTC outcomes in MEN2 patients independent of genotype.  The aim of this study is to 
examine intra- and inter-familial variability of MTC within families with the same germline 
RET codon mutation. 
Methods 
Approval from both the University of Texas MD Anderson Cancer Center (MDACC) 
and Graduate School of Biomedical Sciences (GSBS) institutional review boards were 
obtained for this retrospective chart review.     
Participants 
Pedigrees of families with MEN2A were acquired through institutional surgical and 
genetic counseling databases.  Almost all pedigrees were taken by one of three certified 
genetic counselors with expertise in MEN2A.  According to standard cancer pedigree 
nomenclature, information obtained in each pedigree included a minimum of two generations 
above the family member interviewed.  Targeted questions were asked about each family 
member’s history of MTC including the stage, and treatment, genetic testing status, and 
whether prophylactic thyroidectomy was performed.  Each family member’s age of cancer 
diagnosis and current age or age of death was recorded [19].   
Pedigrees had at least one MDACC patient and were not separated for related patients 
and are updated as patients follow-up.  If the pedigree had not been updated within the past 
two years, ages were calculated to reflect what was known at last follow-up.  We reviewed 
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each pedigree for RET mutation positive family members.  Any family member with a 
diagnosis of MTC, pheochromocytoma, or primary hyperparathyroidism was presumed to be 
a RET mutation carrier.  Obligate carriers were also recorded as RET mutation carriers.  The 
proband was defined as the first person diagnosed with MTC.  
Each RET mutation carrier was classified by MTC status (figure 1). 
Figure 1: RET Mutation Carrier Classification 
 
RET mutation carriers were classified into the above groups.  Information for 
MDACC patients was obtained from the medical record and information about outside 
patients was recorded based on family report. 
 
  For patients with MTC, MTC status was recorded both at the time of diagnosis and 
at the patient’s most advanced MTC stage.  Those with an MTC diagnosis were also recorded 
as having progressive or non-progressive MTC.  Progression was defined as clear 
MTC Status 
No MTC 
Prophylactic 
Thyroidectomy 
Thyroid Intact: 
MDACC 
Screening 
Thyroid Intact: 
Family Report 
MTC 
Diagnosis 
No Metastases 
Local 
Metastases 
Distant 
Metastases 
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radiographic growth of MTC, a calcitonin doubling time of less than two years, development 
of new metastases, or MTC-related death.  
   Ages were recorded at the time of prophylactic thyroidectomy or last follow-up if 
the patient did not have a thyroidectomy for those without MTC and at the time of MTC 
diagnosis and most advanced MTC stage for those with MTC.  We also recorded how 
patients came to clinical attention and whether they presented due to symptoms of MTC or 
through screening due to family history or a positive RET test.    
Pedigrees with fewer than four RET mutation carriers, an unknown mutated codon or 
variant of uncertain significance (VUS) were excluded.  Individuals who tested negative for 
the familial RET mutation, whose RET status was unclear, and those who had an intact 
thyroid with elevated calcitonin but no clear diagnosis of MTC were excluded from the 
study. 
Statistical Analysis 
The following calculations were performed for each pedigree: (1) mean age and 
standard error of RET carriers with no MTC (2) mean age and standard error of MTC 
diagnosis (3) proportion of carriers with MTC who had metastases at diagnosis (4) 
proportion of carriers with MTC who had metastases at most advanced MTC stage (5) 
proportion of carriers with MTC who had disease progression (figure 2). 
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Calculations performed at the time of most advanced MTC stage included only 
patients seen at MDACC to confirm the diagnosis. 
Differences in the mean age of individuals with and without MTC between families 
with mutations in the same codon were compared to each other using one-way analysis of 
variance (ANOVA) with SPSS21.  If the resulting p-value from the ANOVA omnibus test 
was <0.05, Tukey’s post-hoc test was used to evaluate all two-way differences.  Differences 
in proportion of MTC metastases and MTC progression between families with mutations in 
the same codon were assessed using Fisher’s exact test using STATA10 software.  
Significant differences were achieved if p<0.05.    
 
Figure 2: Pedigree calculations 
 
 
 
* Last follow-up applies only to MTC-free patients who have not had a thyroidectomy.  The  
 
above calculations were performed for each pedigree.  Differences in each variable were  
 
compared between families with the same mutated codon.   
Approach 
Time of Presentation 
or Last Follow-up* 
Mean Age: MTC-Free 
Mean Age: MTC 
Diagnosis 
Proportion with 
Metastases 
Proportion with Metastases 
at Most Advanced MTC 
Stage 
Proportion with MTC 
Progression  
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Results 
A total of 175 pedigrees were reviewed with mutations identified in 11 codons (table 
1).  
Table 1: Pedigrees Arranged by Mutated Codon and ATA Risk Level 
Mutated 
Codon 
Number of 
Pedigrees Reviewed 
(Number Included) 
Number of RET 
Mutation Carriers 
Number of RET 
Mutation Carriers with 
MTC (%) 
Number of Affected 
Family Members 
Included 
804 12 -- -- -- 
891 5 -- -- -- 
666 3 -- -- -- 
791* 3 -- -- -- 
790 1 -- -- -- 
912 1 -- -- -- 
891+791* 1 -- -- -- 
Total Pedigrees Risk Level A: 26 
620 8 -- -- -- 
611 2 -- -- -- 
609 21 (13) 92 46 (50) 92 
618 20 (7) 41 22 (54) 41 
Total Pedigrees Risk Level B: 51 
634 34 (13) 152 113 (74) 152 
Total Pedigrees Risk Level C: 34 
Unknown Codon Mutated/ Risk Level: 9 
*Patient had bi-allelic RET mutations.  Pedigrees with fewer than four affected family members were 
excluded from the study. 
 
Due to limitations in the number of families and affected members, comparisons of mean 
ages were restricted to codons 609 (92 individuals from 13 families), 618 (41 individuals 
from 7 families), and 634 (152 individuals from 13 families) and comparisons of proportions 
were limited to codon 634.  The median age of all family members, the percent of patients 
seen at MDACC, the percent of patients with symptomatic presentation, and the range of 
years of first MTC diagnosis representing each codon were recorded (table 2).   
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Table 2: Each Codon Represented by Age, Patient Ascertainment, Patient 
Presentation and Year of First MTC Diagnosis 
 Codon 634 Codon 609 Codon 618 
Patient Ascertainment    
MDACC 94 (62%) 30 (33%) 9 (22%) 
Family Report 58 (38%) 62 (67%) 32 (78%) 
Patient Presentation    
Symptomatic 39 (26%) 17 (18%) 8 (20%) 
Screened 113 (74%) 75 (82%) 33 (80%) 
Range of First MTC Diagnosis 1944-1992 1970-2011 1969-2001 
Range of Ages  2-68 2-79 2-91 
Median Age MTC Diagnosis  26 44 37 
Median Age MTC-Free  25 28 30 
The range and median age in years of family members representing each codon 
was recorded.   
 
Patient MTC Status 
Overall, 133 patients were MTC-free with 50 having no evidence of MTC upon 
prophylactic thyroidectomy, 11 having no evidence of MTC upon screening at MDACC, and 
72 having no evidence of MTC based on family report.  There were 211 patients with an 
MTC diagnosis.  Among these patients, 178 had no metastases, 28 had local metastases, and 
5 had distant metastases.   
Statistical Analyses 
 Mean Ages 
  Among families with a mutation in codon 634, differences in mean age of MTC 
diagnosis was observed after excluding individuals with symptomatic presentation (p=0.014).  
Pedigree 4 had an older age of MTC diagnosis (35.6 years) than pedigree 12 (12.5 years) and 
pedigree 68 has an older age of MTC diagnosis (40.6 years) than pedigrees 12 and 102 (5 
years, figure 3).   
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Figure 3: Mean age of MTC Diagnosis Excluding Individuals With Symptomatic Presentation  
 
for Families with Mutations in Codon 634 
 
 
Significant differences were found among the average age of MTC diagnosis after excluding 
 
individuals with symptomatic presentation for families with a mutation in codon 634.  Pair- 
 
wise differences are indicated by colored astrices. 
 
Among pedigrees with an older mean age of MTC diagnosis, pedigree 4 is 
represented by 9 family members with 6 being in the same generation or a generation above 
the proband.  Pedigree 68 is represented by family members in the same generation or a 
generation above the proband.  Among pedigrees with a younger mean age of MTC 
diagnosis, both pedigrees 12 and 102 were represented by family members in the same 
generation or generations below the proband. 
10 
 
Significant differences in mean age were found among MTC-free family members 
with a mutation in codon 609 (p=0.011) with pedigree 126 having an older mean age (52 
years) than pedigree 55 (4 years, figure 4).  The difference was maintained after excluding 
individuals with prophylactic thyroidectomies (p=0.006).  In this analysis, pedigree 5 has an 
older mean age (76 years) than pedigrees 131 (23 years), 150 (14 years), and 167 (25 years) 
and pedigree 126 has an older mean age (58 years) than pedigree 150 (14 years, figure 4).
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Figure 4: Mean Age of MTC-Free Family Members for Families with Mutations in Codon 609 
  
Significant differences were found among the mean age of MTC-free individuals even after excluding those with prophylactic thyroidectomies for  
 
families with a mutation in codon 609. 
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Among pedigrees with an older mean age of MTC-free family members, pedigree 
126 is represented by primarily by family members in generations below the proband, but the 
familial RET mutation was known in 2008 when the proband’s niece pursued genetic testing 
at 64 years of age.  Subsequent RET testing and medical intervention identified mutation 
carriers who had not yet developed MTC.  Pedigree 5 also has an older mean age of MTC-
free family members and is represented by family members in the generation above the 
proband.  All pedigrees with younger mean age of MTC-free family members (55, 131. 150, 
and 167) are represented by members in the same generation or generations below the 
proband.  
Among families with a mutation in codon 618, differences were found among the 
mean age of MTC-free family members (p=0.001).  None of these individuals had 
prophylactic thyroidectomy.  Pedigrees 41 and 108 had older mean ages (77 and 64 years, 
respectively) than pedigrees 117 and 157 (8 and 7 years, respectively, figure 5).  
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Figure 5: Mean Age of MTC-Free Family Members for Families with Mutations in Codon 618 
  
Significant differences were found among the mean age of MTC-free individuals even after excluding those with prophylactic thyroidectomies for  
 
families with a mutation in codon 618. 
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A significant difference was found when comparing mean ages of MTC diagnosis 
(p=0.036) with pedigree 41 having an older mean age (55 years) than pedigree 119 (20 
years).  There was still a difference after excluding individuals with symptomatic 
presentation (p=0.004) with pedigree 41 having an older mean age (63 years) than pedigrees 
117 and 119 (34 and 16 years, respectively, figure 6).   
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Figure 6: Mean Age of MTC-Free Family Members for Families with Mutations in Codon 618 
  
Significant differences were found among the mean age of MTC-free individuals even after excluding those with prophylactic thyroidectomies for  
 
families with a mutation in codon 618. 
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Pedigree 41 has an older mean age of family members with and without MTC and is 
represented by three generations of RET mutation carriers.  The first MTC diagnosis dates 
back to the mid-1900s, but several MTC diagnoses were not made until genetic testing 
became available in the late 1990’s.  Pedigree 108 has an older mean age of MTC-free 
members and is represented by individuals in generations above the proband.    
Among pedigrees with younger mean ages of family members with and without 
MTC, all pedigrees (117 and 157 for MTC-free and 117 and 119 for MTC diagnoses) are 
represented by individuals in generations below the proband.   
Proportion of family members 
No differences were found among the proportion of family members with metastases 
at presentation or at most advanced MTC stage even after excluding individuals with 
symptomatic presentation.  No differences were found in the proportion of family members 
with MTC progression after excluding individuals with symptomatic presentation even after 
excluding individuals with symptomatic presentation (figure 7). 
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Figure 7: The Proportion of Family Members with Metastases at Diagnosis and Most Advanced MTC Stage 
 
 
 
No differences were found among the proportion of family members with metastases at diagnosis or at most advanced MTC stage.  No differences  
 
were found after excluding individuals with symptomatic presentation (p=0.957 at diagnosis, p=.715 at most advanced MTC stage. 
p=0.341 
p=0.389 
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Discussion 
The current study aims to assess if MEN2A kindreds with the same mutated codon have 
different family histories from each other based on several novel measures of MTC aggressiveness.  
We assessed differences in the mean age of family members with and without MTC controlling for 
prophylactic thyroidectomy to determine whether some families have an earlier age of onset of MTC 
than others.  We assessed differences in the proportion of RET mutation carriers with MTC who had 
metastases both at the time of diagnosis and at the time of most advanced MTC stage and the 
proportion with MTC progression in an attempt to have a measure of biological aggressiveness of 
MTC within each family.  Information about patients followed at outside institutions was included to 
increase the number of eligible patients and to minimize ascertainment bias.   
At first glance, our results suggest that there may be inter-familial variability of MTC age of 
onset between kindreds with mutations in the same codon.  However, two factors appear to 
consistently contribute to inter-familial variability: generational differences in ascertainment of RET 
mutation carriers and the availability of genetic testing.  Families with a younger mean age of 
presentation tend to have a greater proportion of members ascertained in generations below the 
proband, while families with an older mean age of presentation are primarily represented by 
individuals in generations above the proband.  This observation can be appreciated in pedigrees 68 
and 102 (figure 8) and suggests that differences in mean age are due to generational differences of 
family members in relation to the proband.  
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Figure 8: Generational differences in the ascertainment of RET mutation carriers and Mean Age of  
 
MTC Diagnosis 
 
 
Note that pedigree 68 has an older mean age of MTC diagnosis and all family members with MTC  
 
are in the same generation or in a generation above the proband.  Pedigree 102 has a younger mean  
 
age of MTC diagnosis and all family members with MTC are in generations below the proband.  
Pedigree 68 
Mean Age of MTC 
Diagnosis: 40.6 years 
Pedigree 102 
Mean Age of MTC 
Diagnosis: 5.0 years 
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 It is possible that information about the proband’s MTC diagnosis and/or RET 
mutation status is being communicated to family members who opt to have themselves and 
subsequently their children screened.    
It also appears that some families with an older presentation came to attention before 
genetic testing was available.  The ages and years of MTC diagnosis for pedigree 41 
highlight this observation (figure 9).   
Figure 9: The Availability of Genetic Testing and Mean Age of MTC Diagnosis 
 
Note the years of MTC Diagnoses.  Patient 003 did not come to clinical attention until his  
 
sister’s diagnosis of MTC and subsequent RET testing in the mid01990’s.  He and his  
 
daughter were found to carry the familial RET mutation and were positive for MTC on  
 
thyroidectomy. 
Pedigree 41 
Mean Age of MTC Diagnoses: 
63.5 years 
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It also appears that some families with an older presentation came to attention before 
genetic testing was available.  The ages and years of MTC diagnosis for pedigree 41 highlight 
this observation (figure 9).  Additionally, this suggests that since genetic testing has become 
available, family members are opting to test once a mutation is found in the family, making 
young MTC diagnosis likely.  
 Overall, the current study suggests that apparent differences in the presentation of MTC 
between families with the same mutated RET codon are due to ascertainment of family members 
in generations older or younger than the proband and the availability of genetic testing as 
opposed to true biological differences.  To our knowledge, this is the first study attempting to 
quantify familial MTC aggressiveness and compare these measures between families with the 
same mutated RET codon.  The primary limitation is the number of eligible patients.  Several 
analyses could not be performed including assessing differences in families with mutations in 
codons other than 609, 618, and 634.  Additionally, many of our analyses were dependent upon 
the accuracy of the historian and the genetic counselor as a scribe.     
Current MEN2A recommendations state that prophylactic thyroidectomy may be delayed 
if certain criteria are met.  One criterion is a less aggressive family history of MTC, which 
implies that some families have a more aggressive disease course than other with mutations in 
the same codon.  The results of the current study do not support inter-familial variability between 
families with mutations in the same codon based on average age of MTC onset and the 
proportion of the family with metastatic disease at diagnosis and most advanced MTC stage.
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